



**3rd International
Workshop on
Liver & Gut
Fibrosis**

16-17 OCTOBER 2025
VALENCIA, SPAIN

PROGRAMME

THURSDAY 16TH OCTOBER 2025

8:45 - 9:15 am Registration

9:15 am Welcome & overview of the workshop

9:30 - 10:45 am FIBROSIS: STATE-OF-THE-ART

Chairs: Ana Gutiérrez-Casbas and Rubén Francés

9:15 - 9:50 am *Intestinal fibrosis. Michael Scharl (University Hospital Zürich)*

9:50 - 10:25 am *Targeting the gut-liver axis using Yaq001 to prevent occurrence and progression of cirrhosis. Rajiv Jalan (University College London)*

10:30 - 11:00 am Coffee break

11:00 am - 12:30 pm METABOLIC NETWORKS AND PLASTICITY IN FIBROSIS

Chairs: Ana Blas-García and Javier Cubero

11:00 - 11:20 am *Metabolic shifts in hepatic stellate cells: impacts on liver fibrosis. Rubén Nogueiras (Universidad de Santiago de Compostela)*

11:20 - 11:40 am *Microbiota and gut-liver axis in obesity. Yolanda Sanz (IATA, Valencia)*

11:40 am - 12:00 pm *Molecular mechanisms regulating cellular plasticity in liver fibrosis. Kim Ravnskjær (University of Southern Denmark)*

12:00 - 12:20 pm *Epithelial and endothelial plasticity in intestinal fibrosis. Sara Lovisa (Humanitas Research Hospital, Milan)*

12:20 - 12:30 pm General discussion

12:30 - 1:30 pm ORAL PRESENTATIONS

Chairs: Rocío Gallego-Durán and María Dolores Barrachina

12:30 - 12:40 PM: *Blockade of Platelet Activating Factor Receptor pathway with ligand antagonist BN-52021 reduces liver damage and proinflammatory gene expression in fibrotic mice. Enrique Ángel-Gomis (Universidad Miguel Hernández, Alicante)*

12:40 - 12:50 PM: *TWEAK-induced memory in intestinal fibroblasts is associated with epigenetic reprogramming in IBD-susceptibility genes. Cristina Bauset (University College Dublin)*

12:50 - 1:00 PM: *A microfluidic human liver slice model for drug screening: GLP1-R agonist Liraglutide demonstrates antifibrotic activity. María Andrés (Barcelona Liver Bioservices)*

1:00 - 1:10 PM: *Protective role of TPL2/MAP3K8 in hepatic stellate cells (HSC) during liver fibrosis. Sara García (Complutense University, Madrid)*

1:10 - 1:20 PM: *Therapeutic effects of decanoic acid in acute and chronic murine models of colitis. Andrea Cejudo-Garcés (University of Valencia)*

1:20 - 1:30 PM: *Integrative multi-omics of ballooned hepatocytes in MASH defines a diagnostic histopathological signature. Seray Anak (KU Leuven)*

1:30 - 3:00 pm Lunch

3:00 - 4:15 pm ROLE OF THE IMMUNE RESPONSE-INTERACTOME IN FIBROSIS

Chairs: Frank Tacke and Mario Manresa

3:00 - 3:20 pm *Immunomodulatory function of intestinal fibroblasts in cirrhosis. Esther Caparrós (Universidad Miguel Hernández, Elche)*

3:20 - 3:40 pm *Understanding macrophage diversity and dysfunction in Crohn's disease. Colm Bain (University of Edinburgh)*

3:40 - 4:00 pm *Targeting the gut-liver axis in cirrhosis - an update from the clinical perspective.* **Benedikt Simbrunner** (Medical University of Vienna)

4:00 - 4:20 pm *Interaction between stromal and myeloid cells drives tissue remodeling in IBD.* **Gianluca Matteoli** (KU Leuven)

4:20 - 4:35 pm General discussion

4:35 - 5:05 pm FIBROSIS IN OTHER ORGANS AND TISSUES

Chair: Jordi Gracia-Sancho and Sara Calatayud

4:15 - 5:00 pm *Cellular senescence: search and destroy.* **Manuel Collado** (Universidad de Santiago de Compostela)

5:05 - 5:35 pm Coffee break & Poster session

5:35 - 6:35 pm ORAL PRESENTATIONS

Chairs: Anabel Fernández Iglesias and Jesús Cosín

5:35 - 5:45 PM: *Pressure-induced endothelial fibulin7 modulates HSC phenotype and lowers portal pressure in experimental cirrhosis.* **Raül Pastó** (IDIBAPS, Barcelona)

5:45 - 5:55 PM: *The TNF superfamily factor TWEAK promotes inflammatory stroma-monocyte crosstalk in ulcerative colitis via heterologous NF- κ B/STAT3 signalling.* **Carlos Matellan** (University College Dublin)

5:55 - 6:05 PM: *Combined effect of Atorvastatin and Ambrisentan on the hemodynamic alterations and liver fibrosis in a translational rat model of MASLD with advanced fibrosis.* **María de la Serra** (Vall d'Hebron Research Institute, Barcelona)

6:05 - 6:15 PM: *Targeted anti-MCL1 delivery in senescent cells reduces murine intestinal fibrosis.* **Ana Crespo** (University of Valencia)

6:15 - 6:25 PM: *Dysregulation of the urea cycle enzymes determines a more severe MASLD phenotype in a DIAMOND preclinical model.* **Carola Zurita** (Instituto de Biomedicina de Sevilla)

6:25 - 6:35 PM: *Cardiac fibroblast activation is induced by several integrase inhibitors in vitro.* **Víctor Collado-Díaz** (University of Valencia)

8:30 pm Drinks and canapés. Ateneo Mercantil (Sexta Planta)

FRIDAY 17TH OCTOBER 2025

9:00 - 11:00 am MORBIDITY AND MORTALITY IN FIBROSIS

Chairs: Juan Manuel Pericàs and Yamile Zabana

9:00 - 9:25 am *New therapies in IBD.* **Elena Ricart** (Hospital Clínic Barcelona)

9:25 - 9:50 am *Fibrosis and cancer.* **Beatriz Mínguez** (Hospital Universitari Vall d'Hebron, Barcelona)

9:50 - 10:15 am *Extracellular matrix molecules as biomarkers of gut fibrosis.* **Anja Poulsen** (Rigshospitalet, Copenhagen)

10:15 - 10:40 am *Clinical trials in liver fibrosis: an update.* **Frank Tacke** (Charité – Universitätsmedizin Berlin)

10:40 - 11:00 am General discussion

11:00 am - 12:00 pm Coffee break & Poster session

12:00 - 1:45 pm DRUG DEVELOPMENT IN FIBROSIS

Chairs: Michael Scharl and Nadezda Apostolova

12:00 - 12:25 pm *Novel in vitro models to study anti-fibrotic drugs.* **Luca Urbani** (Roger Williams Institute of Hepatology, London)

12:25 - 12:50 pm *Targeting cellular mechanobiology to address fibrosis in cancer.* **Stephen Thorpe** (University College Dublin)

12:50 - 1:15 pm *Proteolytic enzymes driving macrophage phenotypical shift during fibrotic diseases.* **Anna Moles** (IDIBAPS, Barcelona)

1:40 - 1:50 pm *JAK-STAT pathway targeting as a treatment for inflammatory bowel disease.* **Mark Lowenberg** (Amsterdam UMC)

1:40 - 1:50 pm General discussion

1:30 - 1:45 pm Best Communication Award (sponsored by Biomolecules), Travel Grants (sponsored by PharmaNest) and concluding remarks

2:00 - 3:30 pm Lunch